Related Experiment Video
Updated: Sep 17, 2025
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence
Serge Yaacoub1, Elton Vannoy1, Stefanyda Maslova2
1Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, United States.
Abstract:
Chimeric Antigen Receptor T (CAR-T) cell therapy offers substantial promise for the treatment of brain malignancies, yet its clinical translation remains limited. Tumors such as Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), and Medulloblastoma (MB) are associated with poor prognoses and exhibit limited responsiveness to conventional treatment modalities, including radiotherapy, chemotherapy, and surgical resection. The application of CAR-T cell therapy in these contexts faces significant challenges, primarily in terms of efficient cellular trafficking into the tumor microenvironment and access to heterogeneous tumor regions. Furthermore, CAR-T cell persistence, defined by the long-term survival and functionality of infused cells, remains a critical hurdle in achieving durable therapeutic responses and preventing tumor relapses. This review aims to address the two predominant barriers, trafficking and persistence, by discussing the underlying mechanisms that limit CAR-T cell efficacy in brain tumors, reviewing current strategies aimed at overcoming these challenges, and evaluating novel approaches to enhance the effectiveness of CAR-T therapies in this setting.
Insights
Chimeric Antigen Receptor T (CAR-T) cell therapy shows promise for brain tumors but faces challenges. This review explores strategies to improve CAR-T cell trafficking and persistence for better treatment outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Neuro-oncology
Background:
- Chimeric Antigen Receptor T (CAR-T) cell therapy is a promising approach for brain malignancies like Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), and Medulloblastoma (MB).
- These aggressive brain tumors often show limited response to conventional treatments such as radiotherapy, chemotherapy, and surgery.
- Significant challenges hinder CAR-T cell therapy's effectiveness in the brain, including poor tumor infiltration and limited persistence.
Purpose of the Study:
- To review the primary barriers limiting CAR-T cell therapy efficacy in brain tumors: cellular trafficking and persistence.
- To discuss the mechanisms underlying these limitations.
- To evaluate current and novel strategies for enhancing CAR-T cell performance in neuro-oncology.
Main Methods:
- Literature review of existing studies on CAR-T cell therapy for brain tumors.
- Analysis of mechanisms affecting CAR-T cell trafficking and persistence in the tumor microenvironment.
- Evaluation of innovative approaches to overcome these therapeutic challenges.
Main Results:
- CAR-T cell therapy faces significant hurdles in penetrating the brain tumor microenvironment and reaching diverse tumor regions.
- Maintaining long-term CAR-T cell survival and function (persistence) is crucial for durable responses and preventing relapse.
- Various strategies are being developed to enhance CAR-T cell trafficking and persistence.
Conclusions:
- Overcoming trafficking and persistence barriers is essential for successful CAR-T cell therapy in brain tumors.
- Continued research into novel strategies is needed to improve CAR-T cell efficacy and patient outcomes.
- Enhanced CAR-T cell delivery and sustained functionality hold potential for treating aggressive brain malignancies.
